

# Andrea Pace

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6896807/publications.pdf>

Version: 2024-02-01

111  
papers

5,034  
citations

94381

37  
h-index

98753

67  
g-index

136  
all docs

136  
docs citations

136  
times ranked

5388  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 927-931.	0.8	274
2	Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. <i>Annals of Oncology</i> , 2003, 14, 1722-1726.	0.6	245
3	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 110-119.	5.1	238
4	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Annals of Oncology</i> , 2013, 24, 454-462.	0.6	232
5	The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute's Common Toxicity Scale. <i>Journal of the Peripheral Nervous System</i> , 2007, 12, 210-215.	1.4	204
6	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology</i> , The, 2017, 18, e330-e340.	5.1	195
7	Vitamin E neuroprotection for cisplatin neuropathy. <i>Neurology</i> , 2010, 74, 762-766.	1.5	174
8	Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2006, 11, 135-141.	1.4	141
9	End of life issues in brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2009, 91, 39-43.	1.4	137
10	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , 2014, 25, 257-264.	0.6	136
11	Temozolomide as salvage treatment in primary brain lymphomas. <i>British Journal of Cancer</i> , 2007, 96, 864-867.	2.9	135
12	Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 114.	1.0	133
13	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , 2004, 40, 1682-1688.	1.3	118
14	Early rehabilitation after surgery improves functional outcome in inpatients with brain tumours. <i>Journal of Neuro-Oncology</i> , 2012, 107, 537-544.	1.4	112
15	Free Flap Reconstruction of the Sole of the Foot with or without Sensory Nerve Coaptation. <i>Plastic and Reconstructive Surgery</i> , 2002, 109, 2314-2322.	0.7	105
16	Cognitive rehabilitation for early post-surgery inpatients affected by primary brain tumor: a randomized, controlled trial. <i>Journal of Neuro-Oncology</i> , 2013, 114, 93-100.	1.4	104
17	Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 10.	3.5	89
18	Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. <i>Journal of Neuro-Oncology</i> , 2011, 104, 205-214.	1.4	87

#	ARTICLE	IF	CITATIONS
19	Levetiracetam therapy in patients with brain tumour and epilepsy. <i>Journal of Neuro-Oncology</i> , 2006, 80, 97-100.	1.4	76
20	Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. <i>Journal of Neuro-Oncology</i> , 2013, 113, 313-325.	1.4	74
21	?-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. <i>International Journal of Cancer</i> , 2003, 104, 243-250.	2.3	72
22	Outcome and tolerability of topiramate in brain tumor associated epilepsy. <i>Journal of Neuro-Oncology</i> , 2008, 86, 61-70.	1.4	72
23	Standard (60ÂGy) or Short-Course (40ÂGy) Irradiation Plus Concomitant and Adjuvant Temozolomide for Elderly Patients With Glioblastoma: A Propensity-Matched Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 109-115.	0.4	67
24	Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. <i>Journal of Neurology</i> , 2011, 258, 2100-2104.	1.8	61
25	Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. <i>Journal of Neuro-Oncology</i> , 2013, 113, 293-303.	1.4	59
26	Quality of Care and Rehospitalization Rate in the Last Stage of Disease in Brain Tumor Patients Assisted at Home: A Cost Effectiveness Study. <i>Journal of Palliative Medicine</i> , 2012, 15, 225-227.	0.6	54
27	Cognitive impairment in primary brain tumors outpatients: a prospective cross-sectional survey. <i>Journal of Neuro-Oncology</i> , 2013, 112, 455-460.	1.4	53
28	IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. <i>Journal of Neuro-Oncology</i> , 2014, 118, 377-383.	1.4	53
29	The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 60.	3.5	51
30	Epilepsy in the end-of-life phase in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 111, 83-86.	1.4	51
31	Supportive care in neurooncology. <i>Current Opinion in Oncology</i> , 2010, 22, 621-626.	1.1	45
32	Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. <i>Journal of Neuro-Oncology</i> , 2012, 106, 651-656.	1.4	43
33	Predictors of survival and effect of short (40ÂGy) or standard-course (60ÂGy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015, 125, 359-367.	1.4	42
34	Mesial temporal cortex hypoperfusion is associated with depression in subcortical stroke.. <i>Stroke</i> , 1994, 25, 980-985.	1.0	41
35	Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1996, 61, 409-411.	0.9	41
36	Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients. <i>Neurosurgical Focus</i> , 2014, 37, E5.	1.0	41

#	ARTICLE	IF	CITATIONS
37	Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. <i>Neurological Sciences</i> , 2009, 30, 353-359.	0.9	40
38	Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?. <i>Clinical Breast Cancer</i> , 2007, 7, 550-554.	1.1	38
39	Weight of epilepsy in brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2014, 118, 385-393.	1.4	37
40	Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. <i>Neuroradiology</i> , 2015, 57, 1269-1280.	1.1	37
41	Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CIPN-RONS study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 127-135.	1.4	36
42	Quality-of-life assessment in patients who had been surgically treated for cerebellar pilocytic astrocytoma in childhood. <i>Journal of Neurosurgery</i> , 2002, 96, 229-234.	0.9	35
43	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). <i>European Journal of Cancer</i> , 2013, 49, 2910-2918.	1.3	35
44	Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial. <i>Head and Neck</i> , 2016, 38, E2118-21.	0.9	32
45	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. <i>European Journal of Neurology</i> , 2019, 26, 639-650.	1.7	29
46	Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. <i>Journal of Neuro-Oncology</i> , 2008, 90, 217-221.	1.4	28
47	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. <i>BMC Cancer</i> , 2009, 9, 101.	1.1	28
48	Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. <i>Breast Cancer Research</i> , 2017, 19, 46.	2.2	28
49	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 391-397.	1.1	27
50	Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumor-related epilepsy: a pilot study. <i>Epileptic Disorders</i> , 2012, 14, 388-397.	0.7	26
51	Factors affecting 18F FDOPA standardized uptake value in patients with primary brain tumors after treatment. <i>Nuclear Medicine and Biology</i> , 2015, 42, 355-359.	0.3	26
52	Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 347.	3.5	26
53	Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. <i>Italian Journal of Neurological Sciences</i> , 1997, 18, 73-79.	0.1	25
54	Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 33.	3.5	24

#	ARTICLE	IF	CITATIONS
55	Rehabilitation pathways in adult brain tumor patients in the first 12 months of disease. A retrospective analysis of services utilization in 719 patients. <i>Supportive Care in Cancer</i> , 2016, 24, 4801-4806.	1.0	24
56	Chemotherapy in neoplastic meningitis. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 194-200.	2.0	23
57	Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association) Tj ETQq1 1 0.784314 rgBT /Over Neuro-Oncology, 2019, 145, 115-123.	1.4	23
58	End-of-life care in patients with primary malignant brain tumors: early is better. <i>Neuro-Oncology</i> , 2016, 18, 7-8.	0.6	22
59	Weekly schedule of vinorelbine in pretreated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 223-229.	1.1	21
60	Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients. <i>Journal of Neuro-Oncology</i> , 2008, 88, 331-337.	1.4	21
61	Epilepsy in the end of life phase of brain tumor patients: a systematic review. <i>Neuro-Oncology Practice</i> , 2014, 1, 134-140.	1.0	21
62	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	1.4	20
63	The influence of patient sex on clinical approaches to malignant glioma. <i>Cancer Letters</i> , 2020, 468, 41-47.	3.2	20
64	Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. <i>Journal of Neuro-Oncology</i> , 2014, 116, 275-282.	1.4	19
65	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020, 7, 599-612.	1.0	19
66	Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro. <i>Frontiers in Oncology</i> , 2021, 11, 635472.	1.3	19
67	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. <i>Journal of Neuro-Oncology</i> , 2010, 100, 209-215.	1.4	17
68	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 455-462.	1.4	17
69	Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 128.	3.5	16
70	A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 527-535.	1.4	16
71	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.5	16
72	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , 2020, 64, 313-334.	0.3	15

#	ARTICLE	IF	CITATIONS
73	The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. <i>Disease Markers</i> , 2015, 2015, 1-6.	0.6	14
74	Tapentadol in neuropathic pain cancer patients: a prospective open label study. <i>Neurological Sciences</i> , 2017, 38, 1747-1752.	0.9	14
75	Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. <i>Journal of Neuro-Oncology</i> , 2008, 87, 79-84.	1.4	13
76	Improving neuro-oncological patients care: basic and practical concepts for nurse specialist in neuro-rehabilitation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 82.	3.5	13
77	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). <i>European Journal of Cancer</i> , 2021, 155, 179-190.	1.3	13
78	Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 38.	3.5	12
79	Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	12
80	Headache as a presenting symptom of glioma: A cross-sectional study. <i>Cephalalgia</i> , 2018, 38, 730-735.	1.8	12
81	Comorbidities in elderly patients with glioblastoma: a field-practice study. <i>Future Oncology</i> , 2019, 15, 841-850.	1.1	12
82	Depression in Patients with High-grade Glioma: Results of the Glioma Project. <i>Neurosurgery</i> , 2005, 56, E629-E629.	0.6	11
83	Perfusion Computed Tomography (PCT) adopting different perfusion metrics: Recurrence of brain metastasis or radiation necrosis?. <i>European Journal of Radiology</i> , 2012, 81, 1246-1252.	1.2	11
84	Home care for brain tumor patients. <i>Neuro-Oncology Practice</i> , 2014, 1, 8-12.	1.0	11
85	Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report. <i>Oncology Letters</i> , 2016, 12, 2716-2719.	0.8	11
86	Neuroprotective strategies in the prevention of chemotherapy-induced neuropathies. <i>Supportive Care in Cancer</i> , 2013, 21, 1-2.	1.0	10
87	Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma. <i>Cells</i> , 2022, 11, 263.	1.8	10
88	Neurotoxicity of antitumoral IL-2 therapy: Evoked cognitive potentials and brain mapping. <i>Italian Journal of Neurological Sciences</i> , 1994, 15, 341-346.	0.1	8
89	Vastus lateralis myofascial free flap for tongue reconstruction and hypoglossal-femoral anastomosis: neurophysiological study. <i>Neurological Sciences</i> , 2019, 40, 553-559.	0.9	8
90	Open Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical Series. <i>World Neurosurgery</i> , 2019, 127, e751-e760.	0.7	7

#	ARTICLE	IF	CITATIONS
91	Neurocognitive evaluation in older adult patients affected by glioma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 701-708.	0.5	7
92	Neurophysiological evaluation of sexual dysfunction in patients operated for colorectal cancer. <i>Clinical Autonomic Research</i> , 1998, 8, 353-357.	1.4	6
93	Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. <i>Anti-Cancer Drugs</i> , 2007, 18, 687-692.	0.7	6
94	Kyphoplasty with purified silicone VK100 (Elastoplasty) to treat spinal lytic lesions in cancer patients: A retrospective evaluation of 41 cases. <i>Clinical Neurology and Neurosurgery</i> , 2018, 171, 184-189.	0.6	6
95	Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. <i>Journal of Cancer Survivorship</i> , 2023, 17, 1111-1130.	1.5	6
96	Temozolomide Low-dose Chemotherapy in Newly Diagnosed Low-grade Gliomas: Activity, Safety, and Long-term Follow-up. <i>Tumori</i> , 2017, 103, 255-260.	0.6	5
97	Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. <i>Neurology</i> , 2005, 65, 501-502.	1.5	4
98	Palliative and Supportive Care of Patients with Intracranial Glioma. <i>Progress in Neurological Surgery</i> , 2018, 31, 229-237.	1.3	4
99	Major Differences in Lymphocyte Subpopulations Between Cerebrospinal Fluid and Peripheral Blood in Non-Hodgkin Lymphoma Without Leptomeningeal Involvement: Flow Cytometry Evidence of a Cerebral Lymphatic System. <i>Frontiers in Oncology</i> , 2021, 11, 685786.	1.3	4
100	Multidomain and long-term cognitive evaluation in malignant glioma patients. <i>Future Oncology</i> , 2022, , .	1.1	4
101	Subtemporal Transientorial Approach. <i>Journal of Neurosurgery</i> , 2006, 104, 854-855.	0.9	3
102	Gliomas. <i>BioMed Research International</i> , 2014, 2014, 1-2.	0.9	3
103	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2019, 144, 211-216.	1.4	3
104	Docetaxel neuropathy. <i>Neurology</i> , 1996, 47, 615-615.	1.5	2
105	Simultaneous care in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 302-303.	0.6	2
106	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1272-1275.	0.6	2
107	A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?. <i>Future Oncology</i> , 2019, 15, 1717-1727.	1.1	1
108	Palliative Care and Palliative Rehabilitation: Approaches to the End-of-Life. , 2019, , 227-238.		1

#	ARTICLE	IF	CITATIONS
109	Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma. EXCLI Journal, 2021, 20, 1152-1169.	0.5	1
110	The potential role of 18F-FDOPA PET imaging in low-grade gliomas.. Journal of Clinical Oncology, 2014, 32, 2091-2091.	0.8	0
111	Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit "Regina Elena" National Cancer Institute. Neurological Sciences, 0, , .	0.9	0